New Horizon Health Ltd
HKEX:6606
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
CN |
New Horizon Health Ltd
HKEX:6606
|
6.5B HKD | 2 | ||
US |
C
|
Cigna Group
XMUN:CGN
|
89.2B EUR | 2.4 | |
US |
Cigna Corp
NYSE:CI
|
96.3B USD | 2.3 | ||
US |
CVS Health Corp
NYSE:CVS
|
72.2B USD | 1 | ||
US |
Laboratory Corporation of America Holdings
NYSE:LH
|
17.8B USD | 2.2 | ||
DE |
Fresenius SE & Co KGaA
XETRA:FRE
|
15.7B EUR | 0.8 | ||
US |
Quest Diagnostics Inc
NYSE:DGX
|
16B USD | 2.5 | ||
DE |
Fresenius Medical Care AG
XMUN:FME
|
11.9B EUR | 0.9 | ||
DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.9B EUR | 0.9 | |
US |
DaVita Inc
NYSE:DVA
|
12.3B USD | 13.2 | ||
US |
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | -34.9 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.